Wegovy vs Mounjaro: Molecules, Labels, and Trial Data

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate the crowded GLP-1 landscape into plain, evidence-anchored guidance for anyone weighing a metabolic decision. Browse all Peptides & GLP-1 education

What follows is independent editorial analysis. PlexusDx holds no commercial tie to Novo Nordisk, Eli Lilly, or any maker of the brands discussed here.

People type "Wegovy vs Mounjaro" as if the two are interchangeable rivals. In reality they are built on different active ingredients and carry different FDA labels, which makes a straight head-to-head slightly apples-to-oranges. This piece untangles what actually separates them, and closes on the one variable that precedes either prescription: your own metabolic genetics.

Two molecules, not one

Wegovy is semaglutide (Novo Nordisk), a GLP-1 receptor agonist. Mounjaro is tirzepatide (Eli Lilly), a GIP/GLP-1 dual agonist that engages a second incretin receptor as well. Within the wider class, semaglutide, liraglutide, and dulaglutide are GLP-1-selective, while retatrutide is an investigational triple agonist not FDA-approved as of April 2026. Each of these compounds acts on the GLP-1 receptor to slow gastric emptying, blunt post-meal glucose spikes, and amplify satiety signaling.

Where the FDA labels diverge

The label distinction is the crux of this pairing. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes (2022); its weight-management sibling is Zepbound (2023), with an added obstructive sleep apnea indication in 2024 via SURMOUNT-OSA. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management (2021); its diabetes-labeled counterpart is Ozempic (2017), with Rybelsus as oral semaglutide for type 2 diabetes (2019). Older agents include Trulicity/dulaglutide (2014) and Victoza/liraglutide (2010). Retatrutide remains investigational and unapproved.

Reading the trial record

Each brand rests on its own program. Semaglutide is studied through STEP (weight management) and SUSTAIN and SELECT (diabetes and cardiovascular outcomes); tirzepatide through SURMOUNT and SURPASS (weight and diabetes) plus SURMOUNT-OSA. Direct comparisons are limited: SURPASS-2 tested tirzepatide against semaglutide 1 mg in type 2 diabetes, and SUSTAIN 7 pitted semaglutide 1 mg against dulaglutide 1.5 mg. Because populations, doses, and endpoints differ trial to trial, the honest read is per-study rather than sweeping class claims.

Tolerability and the warning they share

Both molecules carry the class boxed warning for thyroid C-cell tumor risk seen in rodent studies, and both are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal complaints — nausea, vomiting, diarrhea, constipation — dominate the side-effect picture and tend to peak during dose escalation. Uncommon but serious events include pancreatitis, gallbladder problems, and acute kidney injury tied to dehydration.

What a month actually costs

As of April 2026, U.S. list prices for the FDA-approved brands span roughly $815 to $1,620 per month according to manufacturer-published pricing. What a patient actually pays hinges on insurance, the indication written on the prescription, savings-card eligibility, and whether a compounded alternative is available through a licensed pathway. The list figure is rarely the out-of-pocket figure.

The biology both molecules inherit

No matter which compound a clinician selects, the same upstream genetic terrain is in play. A common variant in FTO, the fat-mass and obesity-associated gene, tracks with appetite regulation and adiposity set-point; GLP1R encodes the very receptor these drugs bind; MC4R sits at the center of energy balance; and TCF7L2 ties into glucose handling and GLP-1 secretion. These are pathway-level markers — they do not predict how you will respond to Wegovy or Mounjaro specifically, but they describe the landscape a prescriber is stepping into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The differentiator is context: before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 — so you enter the conversation with your provider informed rather than guessing. That is the test-before-you-invest approach.

Related reading on PlexusDx: Wegovy 0.25 Mg 0.5 Ml Pen, Wegovy 2.5 Mg, Wegovy Tablets, and Wegovy Weight Loss Pills.

Editorial note: this comparison is educational. PlexusDx sells only semaglutide and tirzepatide within the GLP-1 category and does not prescribe, sell, or endorse dulaglutide, liraglutide, retatrutide, cagrilintide, or related compounds. The Precision Peptide Genetic Test examines how your genes influence peptide-related pathways; it does not predict response to any specific medication. Speak with a qualified healthcare provider before starting any protocol.

Begin with the biology: take the Precision Peptide Genetic Test, or review the Weight Management Protocols.

Frequently Asked Questions

Is Mounjaro approved for weight loss the way Wegovy is?

Not directly. Mounjaro (tirzepatide) carries an FDA type 2 diabetes label. Its weight-management counterpart is Zepbound, the same molecule under a different approval. Wegovy holds the chronic weight-management indication for semaglutide. Comparing the two therefore mixes a diabetes label with a weight label — a distinction worth keeping straight.

Do Wegovy and Mounjaro contain the same drug?

No. Wegovy is semaglutide, a GLP-1 receptor agonist. Mounjaro is tirzepatide, a GIP/GLP-1 dual agonist that also engages the GIP receptor. They belong to the same therapeutic family but are chemically distinct molecules with different dosing schedules and different trial programs behind them.

Why do both drugs carry an identical safety warning?

The thyroid C-cell tumor boxed warning applies across the incretin class because the signal appeared in rodent studies for these agents collectively. Both are also contraindicated in people with a history of medullary thyroid carcinoma or MEN 2. Discuss your full personal and family history with a provider before starting either.

Will the Precision Peptide Genetic Test tell me which one to pick?

No. It does not predict response to Wegovy, Mounjaro, or any single medication. It maps pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline appetite and energy-balance biology — context that applies whichever molecule a clinician ultimately prescribes.

Continue exploring the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.